News

Entrust Resource Solutions to grow their team

With two acquisitions complete this year, Entrust Resource Solutions are now creating new jobs across the UK by adding a specialist Resourcing Team to their business.

Entrust Resource Solutions recently announced an ambitious growth and acquisition strategy. This started with the addition of two resourcing consultancies to their portfolio, with Horton International (UK) and SCI Search and Selection joining Entrust People. To keep up with their rate of growth and better support their team, the business is now creating a new Resourcing Team.

ScreenIn3D Wins Technology Innovation Prize

ScreenIn3D, a partner of AMSBIO, has received a share of the £1 million plus prize pot and will receive ongoing support from partners of Scottish Edge - a respected regional business support agency.

Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines

Catalent will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms

RSSL opens new microbiology lab to support expansion

Reading Scientific Services Ltd (RSSL) is tripling the size of its pharmaceutical microbiology laboratory with the opening of a new, state-of-the-art facility in Wokingham. The move follows sustained market demand for the consultancy’s microbiological analysis services. It not only provides the operational space to significantly increase capacity, but also signals a commitment to the future expansion of test methods and staff levels.

Ligand subsidiary Vernalis and PhoreMost Limited announce drug discovery collaboration for novel oncology target

San Diego, USA and Cambridge, UK, 12 June, 2019: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

Cambridge Network helps Magna open doors to innovation

An Innovation Day focused on the future of mobility has enabled leading global automotive supplier Magna International to make important connections with researchers, start-ups and companies in and around Cambridge.

Why investors trust their gut about the human microbiome

The increasing popularity of the human microbiome in biotech has become a source of scientific and investor excitement in recent years. Microbiomes, or the genes of a community of microbial cells (or microbiota) which the body is host to, have unexpected benefits and implications for overall health, from regulating the immune system, to influencing conditions such as obesity, diabetes, cancer and aging.

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.

British Company Behind Groundbreaking Breast Cancer Treatment

Astex welcomes positive, new data showing breast cancer drug, Kisqali® (ribociclib), cuts risk of death by up to a third when given with hormone therapy

Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)

• Cedazuridine and decitabine, administered orally as a fixed-dose combination (ASTX727), met the primary endpoint of decitabine exposure equivalence of total 5-day dosing between oral ASTX727 and IV decitabine in the phase 3 ASCERTAIN study in MDS and CMML patients

• The study confirmed that the safety profile and clinical activity of the cedazuridine and decitabine fixed-dose combination was similar to that observed in the phase 1/2 study and similar to the expected clinical profile of decitabine IV

My Account